Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SHR-1210”

99 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 99 results

Testing effectiveness (Phase 2)UnknownNCT04930315
What this trial is testing

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Zhejiang University 78
Not applicableWithdrawnNCT04420130
What this trial is testing

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Who this might be right for
Pancreatic CancerLiver Metastasis
Yanqiao Zhang
Testing effectiveness (Phase 2)UnknownNCT04014101
What this trial is testing

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03950271
What this trial is testing

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Henan Cancer Hospital 25
Not applicableUnknownNCT04889768
What this trial is testing

HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis

Who this might be right for
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
Zhejiang Cancer Hospital 46
Early research (Phase 1)UnknownNCT03527251
What this trial is testing

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Sun Yat-sen University 10
Testing effectiveness (Phase 2)Study completedNCT03755440
What this trial is testing

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Who this might be right for
Gastric Cancer Stage IVEBV
Sun Yat-sen University 6
Testing effectiveness (Phase 2)Ended earlyNCT04294784
What this trial is testing

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Who this might be right for
Gastric CancerGastroEsophageal Cancer
Huazhong University of Science and Technology 58
Not applicableUnknownNCT03722875
What this trial is testing

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 45
Testing effectiveness (Phase 2)UnknownNCT04297202
What this trial is testing

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University 20
Large-scale testing (Phase 3)Study completedNCT03691090
What this trial is testing

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Who this might be right for
Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd. 596
Testing effectiveness (Phase 2)UnknownNCT04035876
What this trial is testing

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Who this might be right for
Hepatocellular CarcinomaLiver Transplant
Zhejiang University 120
Early research (Phase 1)Ended earlyNCT05799183
What this trial is testing

A SHR-1210 BE Study on Healthy Subjects

Who this might be right for
Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd. 12
Testing effectiveness (Phase 2)UnknownNCT03827837
What this trial is testing

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Who this might be right for
Renal Cell CarcinomaUrothelial CarcinomaCervical Cancer+2 more
Jiangsu HengRui Medicine Co., Ltd. 265
Not applicableStudy completedNCT04181645
What this trial is testing

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer Stage IV
RenJi Hospital 40
Testing effectiveness (Phase 2)Ended earlyNCT03645876
What this trial is testing

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd. 12
Testing effectiveness (Phase 2)UnknownNCT03917966
What this trial is testing

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Who this might be right for
Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University 80
Large-scale testing (Phase 3)Study completedNCT03134872
What this trial is testing

SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+6 more
Jiangsu HengRui Medicine Co., Ltd. 419
Large-scale testing (Phase 3)Study completedNCT03764293
What this trial is testing

Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Who this might be right for
Locally Advanced or Metastatic and Unresectable HCC
Jiangsu HengRui Medicine Co., Ltd. 543
Early research (Phase 1)Study completedNCT03945604
What this trial is testing

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Who this might be right for
Triple Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 32
Load More Results